CA2154170A1 - Cyclic imide thione activated polyalkylene oxides - Google Patents

Cyclic imide thione activated polyalkylene oxides

Info

Publication number
CA2154170A1
CA2154170A1 CA002154170A CA2154170A CA2154170A1 CA 2154170 A1 CA2154170 A1 CA 2154170A1 CA 002154170 A CA002154170 A CA 002154170A CA 2154170 A CA2154170 A CA 2154170A CA 2154170 A1 CA2154170 A1 CA 2154170A1
Authority
CA
Canada
Prior art keywords
polyalkylene oxides
activated polyalkylene
cyclic imide
imide thione
thione activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002154170A
Other languages
French (fr)
Other versions
CA2154170C (en
Inventor
Richard B. Greenwald
Anthony J. Martinez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzon Pharmaceuticals Inc
Original Assignee
Richard B. Greenwald
Anthony J. Martinez
Enzon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richard B. Greenwald, Anthony J. Martinez, Enzon, Inc. filed Critical Richard B. Greenwald
Publication of CA2154170A1 publication Critical patent/CA2154170A1/en
Application granted granted Critical
Publication of CA2154170C publication Critical patent/CA2154170C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/16—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Water-soluble cyclic imide thione activated polyalkylene oxides having improved hydrolytic stability are disclosed. Methods of forming and conjugating the activated polyalkylene oxides with biologically active nucleophiles are also disclosed.
CA002154170A 1993-01-19 1994-01-18 Cyclic imide thione activated polyalkylene oxides Expired - Fee Related CA2154170C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/006,247 1993-01-19
US08/006,247 US5349001A (en) 1993-01-19 1993-01-19 Cyclic imide thione activated polyalkylene oxides
PCT/US1994/000578 WO1994017039A1 (en) 1993-01-19 1994-01-18 Cyclic imide thione activated polyalkylene oxides

Publications (2)

Publication Number Publication Date
CA2154170A1 true CA2154170A1 (en) 1994-08-04
CA2154170C CA2154170C (en) 2004-12-14

Family

ID=21719993

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002154170A Expired - Fee Related CA2154170C (en) 1993-01-19 1994-01-18 Cyclic imide thione activated polyalkylene oxides

Country Status (8)

Country Link
US (2) US5349001A (en)
EP (1) EP0681572B1 (en)
JP (1) JP3294849B2 (en)
AU (1) AU6089294A (en)
CA (1) CA2154170C (en)
DE (1) DE69428189T2 (en)
DK (1) DK0681572T3 (en)
WO (1) WO1994017039A1 (en)

Families Citing this family (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
USRE38827E1 (en) 1994-07-27 2005-10-11 3M Innovative Properties Company Adhesive sealant composition
US5583114A (en) 1994-07-27 1996-12-10 Minnesota Mining And Manufacturing Company Adhesive sealant composition
US5650234A (en) * 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5639875A (en) * 1995-02-01 1997-06-17 Hybridon, Inc. Methods for H-phosphonate syntheis of oligonucleotides using triphosgene
US5756593A (en) * 1995-05-15 1998-05-26 Enzon, Inc. Method of preparing polyalkyene oxide carboxylic acids
AU5893796A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
AU5893696A (en) * 1995-06-07 1996-12-30 Novo Nordisk A/S Modification of polypeptides
US7883693B2 (en) 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
JP4193917B2 (en) * 1995-12-18 2008-12-10 アンジオデバイス インターナショナル ゲーエムベーハー Crosslinked polymer composition and method of use thereof
US6833408B2 (en) 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US6106828A (en) * 1996-02-15 2000-08-22 Novo Nordisk A/S Conjugation of polypeptides
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
DE69713517D1 (en) 1996-10-15 2002-07-25 Medical Analysis Systems Inc Process for the stabilization of troponin I (CTnI) by conjugation with an active polymer
AU5104098A (en) * 1996-11-14 1998-06-03 Polymer Technology Corporation Use of water soluble enzyme-polymer conjugates for cleaning contact lenses
US5804183A (en) * 1997-01-31 1998-09-08 Enzon, Inc. Arginine deminase derived from mycoplasma arthritidis and polymer conjugates containing the same
US5900402A (en) * 1997-05-29 1999-05-04 Enzon, Inc. Method of reducing side effects associated with administration of oxygen-carrying proteins
US7642323B2 (en) 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
JP4465109B2 (en) * 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド Polymer prodrugs of amino and hydroxyl containing bioactive agents
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6376470B1 (en) 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
MXPA02006216A (en) 1999-12-22 2004-02-26 Nektar Therapeutics Al Corp Sterically hindered derivatives of water soluble polymers.
ES2327606T3 (en) 2000-01-10 2009-11-02 Maxygen Holdings Ltd CONJUGATES OF G-CSF.
DE60138364D1 (en) 2000-02-11 2009-05-28 Bayer Healthcare Llc CLEANING FACTOR VII OR VIIA CONJUGATE
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
KR20030032977A (en) * 2000-07-12 2003-04-26 그리폰 테라퓨틱스, 인코포레이티드 Chemokine receptor modulators, production and use
RU2003109746A (en) * 2000-09-08 2005-01-27 Грифон Терапьютикс, Инк. (Us) SYNTHETIC PROTEINS STIMULATING ERYTHROPOESIS
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
DK1362053T3 (en) * 2001-02-20 2008-03-10 Enzon Inc Terminally branched polymeric linkers and polymeric conjugates containing these
YU48703A (en) 2001-02-27 2006-05-25 Maxygen Aps New interferon beta-like molecules
US6538104B2 (en) 2001-04-27 2003-03-25 Medical Analysis Systems, Inc. Stabilization of cardiac troponin I subunits and complexes
US20030108585A1 (en) * 2001-05-04 2003-06-12 Roe R. Michael Polymer conjugates of insecticidal peptides or nucleic acids or insecticides and methods of use thereof
EP1392339A4 (en) * 2001-05-04 2009-05-27 Univ North Carolina State Polymer conjugates of insecticidal peptides or nucleic acids and methods of use thereof
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
WO2003018665A1 (en) 2001-08-22 2003-03-06 Bioartificial Gel Technologies Inc. Process for the preparation of activated polyethylene glycols
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
NZ532027A (en) 2001-10-10 2008-09-26 Neose Technologies Inc Remodeling and glycoconjugation of peptides
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
CN105131104B (en) 2001-10-10 2018-11-16 诺和诺德公司 The reconstruct and sugar conjugation of peptide
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
JP4272537B2 (en) * 2002-03-13 2009-06-03 北京鍵▲凱▼科技有限公司 Y-shaped branched hydrophilic polymer derivatives, methods for their preparation, binding products of said derivatives and drug molecules, and pharmaceutical compositions comprising said binding products
US7601688B2 (en) * 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
DK1517710T3 (en) 2002-06-21 2011-07-18 Novo Nordisk Healthcare Ag Pegylated factor VII glycoforms
CA2497777A1 (en) * 2002-09-05 2004-03-18 The General Hospital Corporation Modified asialo-interferons and uses thereof
AU2003268463A1 (en) * 2002-09-05 2004-03-29 The General Hospital Corporation Asialo-interferons and the treatment of liver cancer
WO2004110345A2 (en) * 2002-10-29 2004-12-23 Pharmacia Corporation Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2004060405A2 (en) * 2002-12-30 2004-07-22 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
JP2006516548A (en) * 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト Drug delivery from rapidly gelled polymer compositions
KR20060003862A (en) 2003-03-14 2006-01-11 네오스 테크놀로지스, 인크. Branched water-soluble polymers and their eonjugates
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US7932364B2 (en) 2003-05-09 2011-04-26 Novo Nordisk A/S Compositions and methods for the preparation of human growth hormone glycosylation mutants
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
EP1660047B1 (en) 2003-08-13 2013-11-27 Biocon Limited Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
CN102516386A (en) 2003-10-10 2012-06-27 诺沃挪第克公司 Il-21 derivatives
EP2641611A3 (en) 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US20050153371A1 (en) * 2004-01-07 2005-07-14 Ambit Biosciences Corporation Conjugated small molecules
KR101439880B1 (en) 2004-01-08 2014-09-12 라티오팜 게엠베하 O-linked glycosylation of peptides
AU2005319099B2 (en) 2004-02-02 2010-09-16 Ambrx, Inc. Modified human growth hormone
AU2005211362B2 (en) 2004-02-02 2008-03-13 Ambrx, Inc. Modified human interferon polypeptides and their uses
JP2007526317A (en) * 2004-03-01 2007-09-13 エンゾン ファーマスーティカルズ インコーポレイテッド Interferon-beta polymer conjugate
US7351787B2 (en) * 2004-03-05 2008-04-01 Bioartificial Gel Technologies, Inc. Process for the preparation of activated polyethylene glycols
BRPI0510477B1 (en) 2004-04-28 2023-01-17 Angiotech Biomaterials Corporation METHOD FOR FORMING A GEL AND DEVICE FOR USE IN MEDICAL APPLICATIONS
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
CA2910494C (en) 2004-07-19 2018-10-23 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
US8303973B2 (en) 2004-09-17 2012-11-06 Angiotech Pharmaceuticals (Us), Inc. Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
ES2572779T3 (en) 2004-10-29 2016-06-02 Ratiopharm Gmbh Remodeling and glucopegilation of Fibroblast Growth Factor (FGF)
JP4990792B2 (en) 2004-12-22 2012-08-01 アンブレツクス・インコーポレイテツド Compositions of aminoacyl-tRNA synthetases and uses thereof
NZ555386A (en) 2004-12-22 2011-01-28 Ambrx Inc Formulations of human growth hormone comprising a non-naturally encoded amino acid
JP5425398B2 (en) 2004-12-22 2014-02-26 アンブレツクス・インコーポレイテツド Compositions comprising unnatural amino acids and polypeptides, methods relating to unnatural amino acids and polypeptides, and uses of unnatural amino acids and polypeptides
EP1836316A4 (en) 2004-12-22 2009-07-22 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
ES2449195T3 (en) 2005-01-10 2014-03-18 Ratiopharm Gmbh Glycopegylated granulocyte colony stimulating factor
JP2008534640A (en) 2005-04-05 2008-08-28 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー Method for shielding functional site or epitope of protein
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
ATE529442T1 (en) 2005-06-03 2011-11-15 Ambrx Inc IMPROVED HUMAN INTERFERON MOLECULES AND THEIR USES
JP5335422B2 (en) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Selective reduction and derivatization of engineered proteins containing at least one unnatural cysteine
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1951890A4 (en) 2005-11-16 2009-06-24 Ambrx Inc Methods and compositions comprising non-natural amino acids
US7989554B2 (en) * 2006-01-10 2011-08-02 Enzon Pharmaceuticals, Inc. Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid
US20070238656A1 (en) * 2006-04-10 2007-10-11 Eastman Kodak Company Functionalized poly(ethylene glycol)
EP2213733A3 (en) 2006-05-24 2010-12-29 Novo Nordisk Health Care AG Factor IX analogues having prolonged in vivo half life
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
MX2009002526A (en) 2006-09-08 2009-04-16 Ambrx Inc Suppressor trna transcription in vertebrate cells.
DK2061878T3 (en) 2006-09-08 2014-04-07 Ambrx Inc HYBRID SUPPRESSOR TRNA FOR ANIMAL CELLS
EP2615108B1 (en) 2006-09-08 2016-10-26 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and thier uses
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As Methods for the purification of polypeptide conjugates
JP5457185B2 (en) 2006-10-04 2014-04-02 ノヴォ ノルディスク アー／エス Glycerol-linked PEGylated sugars and glycopeptides
US20100041860A1 (en) * 2006-11-10 2010-02-18 Ube Industries, Ltd. Polyimide, diamine compound and method for producing the same
US8507653B2 (en) * 2006-12-27 2013-08-13 Nektar Therapeutics Factor IX moiety-polymer conjugates having a releasable linkage
ATE554785T1 (en) 2007-03-30 2012-05-15 Ambrx Inc MODIFIED FGF-21 POLYPEPTIDES AND THEIR USE
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
TWI486169B (en) * 2007-04-20 2015-06-01 Sigma Tau Rare Diseases S A Enzymatic anticancer therapy
EP2147116B1 (en) * 2007-04-20 2016-03-02 Sigma-Tau Rare Disease Ltd Stable recombinant adenosine deaminase
WO2008137471A2 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
CN101778859B (en) 2007-06-12 2014-03-26 诺和诺德公司 Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
MX2010003979A (en) * 2007-10-16 2010-06-02 Biocon Ltd An orally administerable solid pharmaceutical composition and a process thereof.
EP2930182A1 (en) 2007-11-20 2015-10-14 Ambrx, Inc. Modified insulin polypeptides and their uses
CN101946171B (en) * 2007-12-14 2014-03-12 拜奥蒂乌姆股份有限公司 Fluorescent compounds
SG188143A1 (en) 2008-02-08 2013-03-28 Ambrx Inc Modified leptin polypeptides and their uses
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
US20100004313A1 (en) * 2008-02-29 2010-01-07 Tbd Modified Poloxamers for Gene Expression and Associated Methods
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
CN102232085A (en) 2008-09-26 2011-11-02 Ambrx公司 Modified animal erythropoietin polypeptides and their uses
MX2011003196A (en) 2008-09-26 2011-04-27 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines.
AU2010258752B2 (en) 2009-06-09 2015-07-09 Prolong Pharmaceuticals, LLC Hemoglobin compositions
US8658434B2 (en) * 2009-10-28 2014-02-25 Biotium, Inc. Fluorescent pyrene compounds
BR112012015597A2 (en) 2009-12-21 2017-01-31 Ambrx Inc modified porcine somatotropin peptides and their uses
MX349301B (en) 2009-12-21 2017-07-21 Ambrx Inc Modified bovine somatotropin polypeptides and their uses.
WO2011143274A1 (en) 2010-05-10 2011-11-17 Perseid Therapeutics Polypeptide inhibitors of vla4
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
HUE045845T2 (en) 2010-08-17 2021-12-28 Ambrx Inc Modified relaxin polypeptides and their uses
AR083006A1 (en) 2010-09-23 2013-01-23 Lilly Co Eli FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
AU2012278944B2 (en) 2011-07-05 2015-09-17 Bioasis Technologies Inc. p97-antibody conjugates and methods of use
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
JP6433424B2 (en) 2012-07-31 2018-12-05 バイオアシス テクノロジーズ インコーポレイテッド Dephosphorylated lysosomal storage disease protein and method of use thereof
ES2907763T3 (en) 2012-08-31 2022-04-26 Sutro Biopharma Inc Modified amino acids comprising an azido group
AU2013341711A1 (en) 2012-11-12 2015-05-21 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
JP2016505528A (en) 2012-11-16 2016-02-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Picte-Spengler ligation for chemical modification of proteins
WO2014160438A1 (en) 2013-03-13 2014-10-02 Bioasis Technologies Inc. Fragments of p97 and uses thereof
ES2658039T3 (en) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
NZ730563A (en) 2014-10-14 2019-05-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
EA036697B1 (en) 2014-10-24 2020-12-09 Бристол-Майерс Сквибб Компани Modified fgf-21 polypeptides and uses thereof
CA3052639A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US10391154B2 (en) 2017-07-19 2019-08-27 Leadiant Biosciences Ltd. Compositions and methods for treating or ameliorating fibrosis, systemic sclerosis and scleroderma
CN111094462A (en) 2017-12-26 2020-05-01 贝克顿·迪金森公司 Deep ultraviolet excitable water-solvated polymer dyes
JP2021519841A (en) 2018-03-30 2021-08-12 ベクトン・ディキンソン・アンド・カンパニーＢｅｃｔｏｎ， Ｄｉｃｋｉｎｓｏｎ Ａｎｄ Ｃｏｍｐａｎｙ Water-soluble polymer dye with pendant chromophore
EP3813867A1 (en) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Treatment of lymmphatic metastases
FI3849614T3 (en) 2018-09-11 2024-02-08 Ambrx Inc Interleukin-2 polypeptide conjugates and their uses
JP2022512746A (en) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド Interleukin-10 polypeptide complex, its dimer, and their use
BR112021015832A2 (en) 2019-02-12 2022-01-18 Ambrx Inc Compositions containing antibody-tlr agonist conjugates, methods and uses thereof
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
US20210355468A1 (en) 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia
US20210393787A1 (en) 2020-06-17 2021-12-23 Bioasis Technologies, Inc. Compositions and methods for treating frontotemporal dementia
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
WO2022212899A1 (en) 2021-04-03 2022-10-06 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
WO2024007016A2 (en) 2022-07-01 2024-01-04 Beckman Coulter, Inc. Novel fluorescent dyes and polymers from dihydrophenanthrene derivatives
WO2024044327A1 (en) 2022-08-26 2024-02-29 Beckman Coulter, Inc. Dhnt monomers and polymer dyes with modified photophysical properties

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58103378A (en) * 1981-12-11 1983-06-20 Yamasa Shoyu Co Ltd Optically active diamide derivative
DE3216722A1 (en) * 1982-05-05 1983-11-10 Hoechst Ag, 6230 Frankfurt 4-HALOMETHYLBENZOESAEEUR-ALKYLESTER-IMINE AND METHOD FOR THE PRODUCTION THEREOF
JP2514950B2 (en) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー Chemically modified protein, its production method and intermediate
IE64284B1 (en) * 1987-08-03 1995-07-26 Ddi Pharmaceuticals Conjugates of superoxide dismutase
JPH01235943A (en) * 1988-03-16 1989-09-20 Konica Corp High contrast silver halide photographic sensitive material
HUT64022A (en) * 1989-04-19 1993-11-29 Enzon Inc Process for producing active polyalkileneoxide carbonates for the modification of polypeptides
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5234903A (en) * 1989-11-22 1993-08-10 Enzon, Inc. Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
US5255689A (en) * 1991-04-20 1993-10-26 Rajko Kenda Intercepting apparatus sampling urine for examination purposes
NZ244778A (en) * 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides

Also Published As

Publication number Publication date
CA2154170C (en) 2004-12-14
JP3294849B2 (en) 2002-06-24
EP0681572A1 (en) 1995-11-15
EP0681572B1 (en) 2001-09-05
EP0681572A4 (en) 1995-09-22
US5405877A (en) 1995-04-11
US5349001A (en) 1994-09-20
JPH08506131A (en) 1996-07-02
WO1994017039A1 (en) 1994-08-04
DK0681572T3 (en) 2001-11-12
AU6089294A (en) 1994-08-15
DE69428189D1 (en) 2001-10-11
DE69428189T2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
CA2154170A1 (en) Cyclic imide thione activated polyalkylene oxides
AU7693396A (en) Poly(9,9'-spiro-bisfluorenes), the production and use of same
ZA985831B (en) Conjugate of polyethylene glycol and chitosan.
CA2103829A1 (en) Peg-interferon conjugates
AU5433494A (en) Injector and use of the same
AU5643698A (en) Common rail and method of manufacturing the same
EP0722507A4 (en) Detection of amplified or deleted chromosomal regions
AU5643798A (en) Common rail and method of manufacturing the same
CA2251087A1 (en) Injection formulations of avermectins and milbemycins based on castor oil
AU4479997A (en) Sustained delivery device and methods of making and using the same
AU4939493A (en) Posts, beams and the like, and method of making same
CA2182522A1 (en) Process for the preparation of 4,6-dichloropyrimidine
CA2368400A1 (en) Macrolides with anti-inflammatory activity
AU6772694A (en) Insecticidal pteridines and 8-deazapteridines
AU1067599A (en) Peptide compositions for the treatment and prevention of hiv infection
CA2019812A1 (en) Novel 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-ones and their use in the prevention or treatment of aids
CA2025855A1 (en) Pharmaceutical Compositions Having Activity on the Cutaneous Microcirculation
AU8625991A (en) D-pantolactone hydrolase and production thereof
AU4995793A (en) Biological applications of alkaloids derived from the tunicate eudistoma sp.
AU2651297A (en) Indolyl-substituted uracil derivatives and herbicides comprising them as active ingredients
DE69406686D1 (en) Esteramide copolymers and their production
AU1311595A (en) Novel quinoxalines and drugs prepared therefrom
AU6263596A (en) Laser range finding and detonating device
IL98544A0 (en) Oxido reductase enzyme system obtainable from p.chrysogenum,its preparation and its use
AU1726695A (en) Turcasarins, novel expanded porphyrins, and uses thereof

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140120